-- Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q1 Revenue $216,000, vs. Street Est of $254,000
4:10PM ET 5/12/2022 MT Newswires...
Quotes Snapshot > VRDN
Viridian Therapeutics Inc VRDN:NASDAQ
Last Price$13.04Cboe Real-Time Last Sale as of 3:22PM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.03(0.23%)
Bid (Size)$13.01 (21)
Ask (Size)$13.14 (400)
Day Low / High$12.76 - 13.33
Volume126.3 K
Read more news Recent News
Insider Sell: Viridian Therapeutics
5:33PM ET 5/04/2022 MT NewswiresJonathan Violin, Director, Chief Executive Officer, on May 02, 2022, sold 30,000 shares in Viridian Therapeutics (VRDN) for $391,200. Following the Form 4...
Viridian Therapeutics Secures Credit Facility for Up to $75 Million From Hercules Capital
4:36PM ET 4/04/2022 MT NewswiresViridian Therapeutics (VRDN) said Monday it has struck a debt financing deal with Hercules Capital (HTGC) for up to $75 million. Viridian said it drew an...
Viridian Therapeutics Doses First Subject in Early-Stage Thyroid Eye Disease Trial
5:04PM ET 3/21/2022 MT NewswiresViridian Therapeutics (VRDN) said Monday it dosed the first subject in an early-stage trial of VRDN-002 for the treatment of thyroid eye disease. The...
View all Commentary and Analysis
Viridian Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
12:16PM ET 5/13/2022 Seeking AlphaViridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q1 2022 Results - Earnings Call Transcript
8:32PM ET 5/12/2022 Seeking AlphaViridian Therapeutics (VRDN) Investor Presentation - Slideshow
2:48PM ET 4/14/2022 Seeking AlphaViridian Therapeutics (VRDN) Investor Presentation - Slideshow
9:39AM ET 3/11/2022 Seeking AlphaCompany Profile
Business DescriptionViridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA. View company web site for more details
| Address | 221 Crescent Street Waltham, Massachusetts 02453 |
| Phone | +1.617.272.4600 |
| Number of Employees | 80 |
| Recent SEC Filing | 05/19/2022 SC 13G |
| President, Chief Executive Officer & Director | Jonathan Violin |
| Chief Financial, Accounting & Business Officer | Kristian Franz Humer |
| Chief Scientist | Vahe Bedian |
| Chief Medical Officer | Barrett Katz |
Company Highlights
| Price Open | $13.16 |
| Previous Close | $13.01 |
| 52 Week Range | $9.47 - 22.00 |
| Market Capitalization | $364.2 M |
| Shares Outstanding | 27.9 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/10/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$7.69 |
| Beta vs. S&P 500 | N/A |
| Revenue | $8.4 M |
| Net Profit Margin | -2,680.16% |
| Return on Equity | -53.19% |
Analyst Ratings as of 11/17/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |